Amydis Diagnostics

Executive Summary

Amydis Diagnostics is pioneering a novel class of diagnostic compounds that enable non-invasive detection and monitoring of disease biomarkers using standard ocular imaging cameras. Founded in 2018 and headquartered in San Diego, the company leverages the eye as a window to systemic health, potentially transforming early diagnosis for neurodegenerative, inflammatory, and metabolic diseases. Currently in Phase 2 development, Amydis aims to validate its lead compound, which targets retinal protein aggregates linked to Alzheimer's disease. If successful, this approach could offer a rapid, cost-effective, and accessible screening tool, reducing reliance on expensive PET scans or invasive lumbar punctures. The company's platform technology has broad applicability across multiple therapeutic areas, positioning it for significant market impact. Despite limited public funding details, Amydis's innovative approach has attracted interest from strategic partners and academic collaborators. Key near-term milestones include completion of ongoing Phase 2 studies and initiation of regulatory discussions with the FDA. The company's progress will depend on robust clinical data, securing additional capital, and establishing commercial partnerships for future launch.

Upcoming Catalysts (preview)

• Q2 2026Phase 2 clinical data readout for lead Alzheimer's diagnostic65% success
• Q3 2026FDA pre-submission meeting or Breakthrough Device designation60% success
• H2 2026Strategic partnership or licensing deal with major diagnostic or pharma company50% success